1. Home
  2. Detail

@ghostmode2932:

♛
♛
Open In TikTok:
Region: US
Wednesday 04 November 2026 22:01:50 GMT
201
7
0
0

Music

Download

No Watermark .mp4 (0MB) No Watermark(HD) .mp4 (0MB) Watermark .mp4 (0MB) Music .mp3

Comments

There are no more comments for this video.
To see more videos from user @ghostmode2932, please go to the Tikwm homepage.

Other Videos
Di ako bakla 🥴💅🏻 DC:@elmerkaison🇵🇭 #rahzeedycabaluna
Di ako bakla 🥴💅🏻 DC:@elmerkaison🇵🇭 #rahzeedycabaluna
Beautiful dance#dance #tiktokdancetrend #treanding #happydance
Beautiful dance#dance #tiktokdancetrend #treanding #happydance




This is one of the hardest conversations in ER/PR-positive, HER2-negative breast cancer survivorship. Hormone therapy can be extremely effective at lowering recurrence risk. But for some people, the side effects can also affect daily life—joint and muscle pain, hot flashes, fatigue, sleep problems, vaginal symptoms, mood changes, and feeling unlike yourself. First, what does the science say? For ER-positive early breast cancer, about 5 years of tamoxifen lowers the annual breast-cancer death rate by roughly 31% compared with not taking tamoxifen. Long-term studies also show a major reduction in recurrence that continues years after treatment ends. For postmenopausal women, aromatase inhibitors such as anastrozole, letrozole, and exemestane can reduce recurrence even more than tamoxifen in appropriate patients. In a large meta-analysis, 5 years of an aromatase inhibitor lowered 10-year breast-cancer mortality by about 15% relative to tamoxifen, and by about 40% relative to receiving no endocrine therapy. But those are relative reductions across large groups. Your personal benefit could be much smaller or much larger depending on your tumor size, lymph nodes, grade, age, genomic testing, and baseline recurrence risk. NCI notes that women at higher recurrence risk generally have more to gain from longer endocrine treatment than women whose baseline risk is already very low. What happens if someone stops endocrine therapy early? This is important. Studies consistently show that people who stop endocrine therapy early or take it inconsistently have higher recurrence and mortality rates than those who complete the recommended treatment. But that does not mean every person who stops their medication will have a recurrence. And it does not mean everyone has the same amount of benefit from continuing. That is why the question should not simply be: “Do I take it or not?” The better question is: “What is MY absolute benefit from this medication, and what other options do I have if I cannot tolerate it?” Quality of life matters too. So if you are hurting every day, tell your oncologist. There may be options such as: Changing from one aromatase inhibitor to another Switching between an aromatase inhibitor and tamoxifen when medically appropriate Taking a brief medically supervised break to determine whether the medication is causing the symptoms Treating joint pain, hot flashes, sleep problems, or vaginal symptoms Physical therapy and regular exercise Checking bone health and vitamin D when appropriate The answer does not always have to be “suffer through it” or “stop completely.” Sometimes the goal is finding a treatment you can actually live with. And this is the number I would ask my oncologist for: “Without hormone therapy, what is my estimated absolute risk of recurrence—and with hormone therapy, what does that number become?” Because a 40% relative risk reduction does not mean everyone’s chance drops by 40 percentage points. For example: If someone’s recurrence risk were 20%, lowering it by 40% relatively would bring it to about 12%—an 8 percentage-point absolute benefit. If someone’s recurrence risk were 5%, the same relative reduction would bring it to about 3%—a 2 percentage-point absolute benefit. Those are just examples, not personal predictions. 🤍 The conversation survivors deserve Cancer treatment is not only about adding years to life. It is also about being able to live those years. There is no shame in saying: “I want to reduce my recurrence risk—but I also need to be able to function, move, work, sleep, and enjoy my life.” That is not giving up. That is a conversation about risk, benefit, and quality of life that every cancer survivor deserves to have with their oncology team. ⚠️ Disclaimer: Never stop endocrine therapy on your own. The risks and benefits are highly individual, and your oncologist can help you weigh recurrence protection against side effects and discuss alternatives. #survivor #cancer #breastcancer #womenshealth #fyp
This is one of the hardest conversations in ER/PR-positive, HER2-negative breast cancer survivorship. Hormone therapy can be extremely effective at lowering recurrence risk. But for some people, the side effects can also affect daily life—joint and muscle pain, hot flashes, fatigue, sleep problems, vaginal symptoms, mood changes, and feeling unlike yourself. First, what does the science say? For ER-positive early breast cancer, about 5 years of tamoxifen lowers the annual breast-cancer death rate by roughly 31% compared with not taking tamoxifen. Long-term studies also show a major reduction in recurrence that continues years after treatment ends. For postmenopausal women, aromatase inhibitors such as anastrozole, letrozole, and exemestane can reduce recurrence even more than tamoxifen in appropriate patients. In a large meta-analysis, 5 years of an aromatase inhibitor lowered 10-year breast-cancer mortality by about 15% relative to tamoxifen, and by about 40% relative to receiving no endocrine therapy. But those are relative reductions across large groups. Your personal benefit could be much smaller or much larger depending on your tumor size, lymph nodes, grade, age, genomic testing, and baseline recurrence risk. NCI notes that women at higher recurrence risk generally have more to gain from longer endocrine treatment than women whose baseline risk is already very low. What happens if someone stops endocrine therapy early? This is important. Studies consistently show that people who stop endocrine therapy early or take it inconsistently have higher recurrence and mortality rates than those who complete the recommended treatment. But that does not mean every person who stops their medication will have a recurrence. And it does not mean everyone has the same amount of benefit from continuing. That is why the question should not simply be: “Do I take it or not?” The better question is: “What is MY absolute benefit from this medication, and what other options do I have if I cannot tolerate it?” Quality of life matters too. So if you are hurting every day, tell your oncologist. There may be options such as: Changing from one aromatase inhibitor to another Switching between an aromatase inhibitor and tamoxifen when medically appropriate Taking a brief medically supervised break to determine whether the medication is causing the symptoms Treating joint pain, hot flashes, sleep problems, or vaginal symptoms Physical therapy and regular exercise Checking bone health and vitamin D when appropriate The answer does not always have to be “suffer through it” or “stop completely.” Sometimes the goal is finding a treatment you can actually live with. And this is the number I would ask my oncologist for: “Without hormone therapy, what is my estimated absolute risk of recurrence—and with hormone therapy, what does that number become?” Because a 40% relative risk reduction does not mean everyone’s chance drops by 40 percentage points. For example: If someone’s recurrence risk were 20%, lowering it by 40% relatively would bring it to about 12%—an 8 percentage-point absolute benefit. If someone’s recurrence risk were 5%, the same relative reduction would bring it to about 3%—a 2 percentage-point absolute benefit. Those are just examples, not personal predictions. 🤍 The conversation survivors deserve Cancer treatment is not only about adding years to life. It is also about being able to live those years. There is no shame in saying: “I want to reduce my recurrence risk—but I also need to be able to function, move, work, sleep, and enjoy my life.” That is not giving up. That is a conversation about risk, benefit, and quality of life that every cancer survivor deserves to have with their oncology team. ⚠️ Disclaimer: Never stop endocrine therapy on your own. The risks and benefits are highly individual, and your oncologist can help you weigh recurrence protection against side effects and discuss alternatives. #survivor #cancer #breastcancer #womenshealth #fyp

About

Legal